摘要
目的探讨替罗非班联合阿司匹林治疗高危非致残性缺血性脑梗死的疗效及对同型半胱氨酸(Hcy)、血管内皮生长因子(VEGF)水平的影响。方法采取随机数字表法将2022年9月至2025年5月医院收治的80例高危非致残性缺血性脑梗死患者分为对照组和观察组,各40例。对照组采取阿司匹林联合氯吡格雷治疗,观察组采取替罗非班联合阿司匹林治疗,均治疗7 d。比较两组的临床疗效、血液流变学指标、血清指标、出血性事件及治疗后3个月的复发情况。结果相较于对照组,观察组的治疗总有效率更高(P<0.05)。治疗后,两组的血液流变学指标均降低,且观察组低于对照组(P<0.05)。治疗后,两组的Hcy水平均降低,VEGF水平均升高,且观察组优于对照组(P<0.05)。两组的出血性事件总发生率及复发率比较,差异无统计学意义(P>0.05)。结论替罗非班联合阿司匹林治疗高危非致残性缺血性脑梗死患者的效果满意,可改善血液流变学,调节Hcy、VEGF水平,且具备一定的安全性。
Objective To investigate the efficacy of tirofiban combined with aspirin in the treatment of high-risk non-disabling ischemic cerebral infarction and its influences on homocysteine(Hcy)and vascular endothelial growth factor(VEGF)levels.Methods A total of 80 patients with high-risk non-disabling ischemic cerebral infarction admitted in hospital from September 2022 to May 2025 were divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated with aspirin combined with clopidogrel,and the observation group was treated with tirofiban combined with aspirin.Both groups were treated for 7 d.The clinical efficacy,hemorheological indexes,serum indexes,hemorrhagic events and recurrence 3 months after treatment were compared between the two groups.Results Compared with the control group,the total effective rate of treatment in the observation group was higher(P<0.05).After treatment,the hemorheological indexes of the two groups were decreased,and those of the observation group were lower than the control group(P<0.05).After treatment,the levels of Hcy in the two groups decreased,and the levels of VEGF increased,and those in the observation group were better than the control group(P<0.05).There were no significant differences in the total incidence of hemorrhagic events and recurrence rate between the two groups(P>0.05).Conclusion Tirofiban combined with aspirin is effective in the treatment of patients with high-risk non-disabling ischemic cerebral infarction.It can improve hemorheology,regulate Hcy and VEGF levels,and has certain safety.
作者
罗勇
LUO Yong(Neurology Department,Shaoyang University Affiliated Second Hospital,Shaoyang 422000,China)
出处
《临床医学研究与实践》
2025年第36期58-61,共4页
Clinical Research and Practice
基金
2022年度邵阳市科技创新指导性项目(No.2022GZ4088)。
